Irene Becklund Sells 8,411 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Irene Becklund sold 8,411 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $308,767.81. Following the completion of the transaction, the insider owned 2,126 shares in the company, valued at $78,045.46. The trade was a 79.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Hims & Hers Health Stock Up 2.1%

Hims & Hers Health stock opened at $35.49 on Friday. The firm has a market cap of $8.08 billion, a price-to-earnings ratio of 65.72, a P/E/G ratio of 6.88 and a beta of 2.41. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. Hims & Hers Health, Inc. has a fifty-two week low of $23.97 and a fifty-two week high of $72.98. The firm has a fifty day moving average price of $41.85 and a two-hundred day moving average price of $48.53.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). The business had revenue of $598.98 million during the quarter, compared to analyst estimates of $578.99 million. Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The company’s revenue for the quarter was up 49.2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.32 earnings per share. As a group, analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health announced that its board has initiated a share buyback plan on Monday, November 17th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 3% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently bought and sold shares of the business. VIRGINIA RETIREMENT SYSTEMS ET Al raised its stake in shares of Hims & Hers Health by 0.8% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,600 shares of the company’s stock valued at $1,452,000 after buying an additional 200 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in Hims & Hers Health by 15.7% in the first quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company’s stock valued at $49,000 after acquiring an additional 227 shares during the period. GAMMA Investing LLC raised its position in Hims & Hers Health by 6.1% in the third quarter. GAMMA Investing LLC now owns 4,098 shares of the company’s stock worth $232,000 after purchasing an additional 236 shares in the last quarter. Concurrent Investment Advisors LLC lifted its stake in Hims & Hers Health by 1.8% during the third quarter. Concurrent Investment Advisors LLC now owns 13,984 shares of the company’s stock worth $793,000 after purchasing an additional 252 shares during the period. Finally, Bessemer Group Inc. boosted its holdings in Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after purchasing an additional 312 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on HIMS shares. Leerink Partnrs upgraded shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, December 4th. BTIG Research reissued a “buy” rating and issued a $85.00 price target on shares of Hims & Hers Health in a report on Tuesday, November 4th. Bank of America raised their price target on shares of Hims & Hers Health from $28.00 to $32.00 and gave the stock an “underperform” rating in a research report on Tuesday, November 4th. Canaccord Genuity Group restated a “buy” rating and set a $68.00 price objective on shares of Hims & Hers Health in a report on Friday, September 12th. Finally, UBS Group set a $32.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $45.50.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers announced a roughly US$200 million investment to expand its New Albany, Ohio operations — a move reporters say could quietly redefine its core strategy by expanding fulfillment/operational capacity and creating ~400 jobs. Investors often view large, strategic capacity investments as potential drivers of revenue growth and margin improvement over time. Is Hims & Hers Health’s US$200 Million Ohio Bet Quietly Redefining Its Core Strategy (HIMS)?
• Positive Sentiment: The company has an active share-repurchase program — the board authorized up to $250M (about 3% of shares) — which can support the stock by reducing float and signaling management confidence in valuation. Hims, Block, and NRG Just Launched Huge Stock Buybacks
• Neutral Sentiment: Analyst / media cautions: a Zacks piece flagged HIMS among high-growth medtech/telehealth names that could slow in 2026 — a reminder that momentum names carry execution and multiple-compression risk. 3 Skyrocketing MedTech Stocks That Might Lose Steam in 2026
• Neutral Sentiment: Large institutional ownership remains significant (e.g., Farallon, Invesco increased stakes), which can stabilize share demand but also concentrate price action; this is background context for liquidity and investor flows. HIMS company page (MarketBeat)
• Negative Sentiment: Several insiders sold shares on Dec. 17 (including Deborah Autor, Irene Becklund, Patrick Carroll and COO Michael Chi) — transactions together total roughly $1.4M+ and include large percentage reductions for some insiders. Concentrated insider selling, particularly from senior executives, can spook momentum traders and suggests some tax/liquidity-driven exits or portfolio trimming. Hims & Hers Health (NYSE:HIMS) Insider Sells $258,952.34 in Stock

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.